

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating ~~[[,]]~~ or ~~remedying or preventing~~ psoriasis in a subject in need thereof, comprising administering to the subject a ~~therapeutic~~ therapeutically effective dose of at least one calcitonin gene-related peptide (CGRP) antagonist compound in a ~~pharmaceutical~~ pharmaceutically acceptable formulation.

2. (Currently Amended) The method according to claim 1, wherein the at least one CGRP antagonist compound is selected from the group consisting of: 4-sulfinyl benzamide compounds, 3,4-dinitrobenzamide compounds, benzamidazoliny l piperadine compounds, anti-CGRP antibodies, ~~CGRP derivatives including the peptide~~ a peptide comprising amino acids 8-37 of SEQ ID NO:1 CGRP 8-37, tryptase active polypeptide, ~~and the compound BIBN4096BS, and compound stabilising tryptase, including heparin.~~

3. (Currently Amended) The method according to claim 1, wherein the at least one CGRP antagonist compound is administered locally, ~~such as topically, dermally, intradermally, or subcutaneously, or via dermal or subcutaneous infusion such as through microdialysis administration.~~

4. (Cancelled)

5. (Original) The method according to claim 1, wherein the CGRP antagonist compound is administered topically.

6-14. (Canceled)

15. (New) The method according to claim 1, wherein the at least one CGRP antagonist is administered topically, dermally, intradermally, subcutaneously, via dermal infusion, or via subcutaneous infusion.

16. (New) The method according to claim 15, wherein via subcutaneous infusion is administration through microdialysis.

17. (New) The method according to claim 1, wherein said at least one CGRP antagonist compound is a polypeptide selected from the group consisting of: a polypeptide of amino acids 8-37 of SEQ ID NO:1, a polypeptides of amino acids 27-37 of SEQ ID NO:1, a polypeptides of amino acids 28-37 of SEQ ID NO:1 and a polypeptides of amino acids 30-37 of SEQ ID NO:1.

18. (New) The method according to claim 1, wherein said at least one CGRP antagonist compound comprises a polypeptide of amino acids 8-37 of SEQ ID NO:1.

19. (New) The method according to claim 1, wherein said at least one CGRP antagonist compound consists essentially of a polypeptide of amino acids 8-37 of SEQ ID NO:1.

20. (New) The method according to claim 1, wherein the at least one CGRP antagonist compound is a CGRP peptide which lacks wild type CGRP activity and binds to CGRP receptor.

21. (New) The method according to claim 20, wherein said at least one CGRP antagonist compound is selected from the group consisting of: a polypeptide of amino acids 8-37 of SEQ ID NO:1, a polypeptides of amino acids 27-37 of SEQ ID NO:1, a polypeptides of amino acids 28-37 of SEQ ID NO:1 and a polypeptides of amino acids 30-37 of SEQ ID NO:1.

22. (New) The method according to claim 1, wherein said at least one CGRP antagonist compound is selected from the group consisting of:

(±)-4- [(2-chlbropenyl) sulfinyl]-N-mothyl-N- (2-methylphenyl)-3-nitrobenzamide;
(+)-4-[(2-chlorophenyl)sulfinyl]-N-methyl-N-(2-methylphenyl)-3-nitrobenzamide;
(-)-4-[(2-chlorophenyl)sulfinyl]-N-methyl-N-(2-methylphenyl)-3-nitrobenzamide;
(±)-4-[(4-chlorophenyl) sulfinyl]-N-methyl-N- (2-methylphenyl)-3-nitrobenzamide;
(±)-N-methyl-N- (2-methylphenyl)-4- [(1-oxido-2-pyridinyl) sulfinyl]-3-nitrobenzamide;
(±)-N-methyl-N-(2-methylphenyl)-3-nitro-4-(2-thiazolysulfinyl) benzamide;
(±)-N-methyl-N-(2-methylphenyl)-4-[(5-methyl-1.,3,4-thiadiazol-2-yl)sulfinyl]-3-nitrobenzamide;

N-[3-[(diethylamino)carbonyl] propyl]-N-(-2ethylphenyl)-3-nitro-4-(2-thiazolyisulfinyl) benzamide;

1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]methylsulfonyliminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine;

1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine;

1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]phenylsulfonyliminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine;

1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine;

1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]methylsulfonyliminomethyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl) piperazine;

1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]phenylsulfonyliminomethyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl) piperazine;

1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine;

1-[4-bromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-3,5-dimethyl-D;

L-phenylalanyl]-4-(1-piperidinyl)-piperidine, 1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(4-pyridinyl) piperazine;

1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(4-pyridinyl) piperazine;

1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine;

1-[3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]
cyanoiminomethyl]-D-tyrosyl]-4-(4-methyl-1-piperazinyl) piperidine;

1-[4-bromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]
cyanoiminomethyl]-3,5-dimethyl-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl) piperidine;

1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl]-1-
piperidinyl]cyanoiminomethyl]-D-phenyl-alanyl]-4-(4-methyl-1-piperazinyl) piperidine;

1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-
piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl) piperidine;

1-[4-amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-
piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine;

1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-
piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine;

1-[3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]
cyanoiminomethyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine;

1-[3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-
piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine;

1-[3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]
cyanoiminomethyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl) piperazine;

1-[3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-
piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl) piperazine;

1-[4-amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-
piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl) piperazine;

1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl) piperazine;

1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-4-methyl-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine;

1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-4-methyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine;

1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]cyanoiminomethyl]-4-methyl-D,L-phenylalanyl]-4-(4-pyridinyl) piperazine;

1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-piperidinyl) piperidine;

1-[4-amino-3,5-dibromo-N-[[4-(7-methoxy-2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine;

1-[4-amino-3,5-dibromo-N-[[4-(5,7-dihydro-6-oxodibenzo[d,f][1,3]-diazepin-5-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine;

1-[4-amino-3,5-dibromo-N-[[4-(7-methoxy-2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl) piperazine;

1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-2(2H)-oxo-imidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl) piperazine;

1-[4-amino-3, 5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]sulfonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl) piperazine;

1-[3,5-dibromo-N-[[4-(7-methoxy-2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-piperidinyl) piperidine;

1-[3,5-dibromo-N-[[4-(7-methoxy-2, 3,4, 5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl) piperazine;

1-[3,5-dibromo-N-[[4-[1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-piperidinyl) piperidine;

1-[3,5-dibromo-N-[[4-[1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl) piperazine;

1-[4-amino-3,5-dibromo-N-[[4-(7-methoxy-2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine;

1-[4-amino-3,5-dibromo-N-[(4-[1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl) piperidine;

and pharmaceutically acceptable salts thereof.